SWTX vs. QGEN, PCVX, ASND, ROIV, RVMD, LNTH, BPMC, BBIO, LEGN, and ELAN
Should you be buying SpringWorks Therapeutics stock or one of its competitors? The main competitors of SpringWorks Therapeutics include Qiagen (QGEN), Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.
SpringWorks Therapeutics vs.
Qiagen (NYSE:QGEN) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations, community ranking and profitability.
70.0% of Qiagen shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 7.6% of SpringWorks Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Qiagen received 148 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. However, 70.63% of users gave SpringWorks Therapeutics an outperform vote while only 60.73% of users gave Qiagen an outperform vote.
Qiagen currently has a consensus target price of $51.50, indicating a potential upside of 11.96%. SpringWorks Therapeutics has a consensus target price of $70.00, indicating a potential upside of 102.14%. Given SpringWorks Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe SpringWorks Therapeutics is more favorable than Qiagen.
Qiagen has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
Qiagen has higher revenue and earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
Qiagen has a net margin of 4.73% compared to SpringWorks Therapeutics' net margin of -203.09%. Qiagen's return on equity of 13.43% beat SpringWorks Therapeutics' return on equity.
In the previous week, SpringWorks Therapeutics had 17 more articles in the media than Qiagen. MarketBeat recorded 24 mentions for SpringWorks Therapeutics and 7 mentions for Qiagen. Qiagen's average media sentiment score of 0.84 beat SpringWorks Therapeutics' score of 0.27 indicating that Qiagen is being referred to more favorably in the media.
Summary
Qiagen beats SpringWorks Therapeutics on 11 of the 18 factors compared between the two stocks.
Get SpringWorks Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SpringWorks Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SWTX) was last updated on 1/20/2025 by MarketBeat.com Staff
Free SWTX Stock Alerts